Coexpression cluster:C166

Full id: C166_Macrophage_Monocytederived_Dendritic_adipose_lymph_CD14_lung

Phase1 CAGE Peaks

Hg19::chr10:80737664..80737698,-	p@chr10:80737664..80737698 -
Hg19::chr10:82173423..82173439,+	p5@FAM213A
Hg19::chr10:82173440..82173452,+	p11@FAM213A
Hg19::chr11:118087684..118087694,-	p@chr11:118087684..118087694 -
Hg19::chr11:118087713..118087733,-	p@chr11:118087713..118087733 -
Hg19::chr11:118087749..118087766,-	p@chr11:118087749..118087766 -
Hg19::chr11:122650064..122650075,+	p15@UBASH3B
Hg19::chr11:122650109..122650120,+	p14@UBASH3B
Hg19::chr11:122650146..122650175,+	p10@UBASH3B
Hg19::chr11:128774561..128774596,-	p1@C11orf45
Hg19::chr11:21934096..21934106,+	p@chr11:21934096..21934106 +
Hg19::chr11:21934119..21934129,+	p@chr11:21934119..21934129 +
Hg19::chr11:21934135..21934146,+	p@chr11:21934135..21934146 +
Hg19::chr11:22174975..22174980,+	p@chr11:22174975..22174980 +
Hg19::chr11:58959504..58959511,+	p@chr11:58959504..58959511 +
Hg19::chr11:58959543..58959563,+	p@chr11:58959543..58959563 +
Hg19::chr11:58959610..58959620,+	p@chr11:58959610..58959620 +
Hg19::chr11:60718699..60718724,-	p13@SLC15A3
Hg19::chr11:60719430..60719439,-	p24@SLC15A3
Hg19::chr11:62344767..62344782,-	p3@TUT1
Hg19::chr11:63964388..63964398,+	p16@STIP1
Hg19::chr11:63964439..63964450,+	p14@STIP1
Hg19::chr12:14721192..14721202,-	p8@PLBD1
Hg19::chr12:16505660..16505685,-	p@chr12:16505660..16505685 -
Hg19::chr12:26484990..26485000,-	p@chr12:26484990..26485000 -
Hg19::chr12:4388020..4388039,+	p9@CCND2
Hg19::chr12:4388045..4388063,+	p18@CCND2
Hg19::chr12:49582225..49582269,-	p7@TUBA1A
Hg19::chr12:53224364..53224373,-	p2@KRT79
Hg19::chr12:56120803..56120814,-	p38@CD63
Hg19::chr12:56120838..56120848,-	p31@CD63
Hg19::chr13:113951188..113951191,+	p21@LAMP1
Hg19::chr13:49086093..49086111,-	p@chr13:49086093..49086111 -
Hg19::chr15:77308164..77308175,+	p10@PSTPIP1
Hg19::chr15:77308178..77308193,+	p11@PSTPIP1
Hg19::chr15:80469727..80469736,+	p8@FAH
Hg19::chr15:80469741..80469772,+	p6@FAH
Hg19::chr15:83779343..83779358,-	p@chr15:83779343..83779358 -
Hg19::chr17:25958114..25958129,+	p3@LGALS9
Hg19::chr17:4642833..4642875,-	p3@CXCL16
Hg19::chr17:62315972..62315978,-	p@chr17:62315972..62315978 -
Hg19::chr17:75276245..75276249,+	p@chr17:75276245..75276249 +
Hg19::chr19:3785229..3785244,-	p5@MATK
Hg19::chr19:3785250..3785292,-	p3@MATK
Hg19::chr19:45418067..45418076,+	p7@APOC1
Hg19::chr19:6680235..6680290,-	p4@C3
Hg19::chr1:111050807..111050828,+	p@chr1:111050807..111050828 +
Hg19::chr1:111050845..111050854,+	p@chr1:111050845..111050854 +
Hg19::chr1:111052907..111052935,-	p@chr1:111052907..111052935 -
Hg19::chr1:111058061..111058076,+	p@chr1:111058061..111058076 +
Hg19::chr1:156510852..156510859,-	p@chr1:156510852..156510859 -
Hg19::chr1:156510877..156510889,-	p@chr1:156510877..156510889 -
Hg19::chr1:203155503..203155528,-	p@chr1:203155503..203155528 -
Hg19::chr1:203198790..203198807,-	p1@CHIT1
Hg19::chr1:27962025..27962032,-	p15@FGR
Hg19::chr1:54707213..54707231,-	p@chr1:54707213..54707231 -
Hg19::chr1:54707235..54707253,-	p@chr1:54707235..54707253 -
Hg19::chr1:54707911..54707917,-	p@chr1:54707911..54707917 -
Hg19::chr1:54707929..54707943,-	p@chr1:54707929..54707943 -
Hg19::chr1:54707952..54707973,-	p@chr1:54707952..54707973 -
Hg19::chr1:54707979..54707987,-	p@chr1:54707979..54707987 -
Hg19::chr20:1875003..1875020,+	p20@SIRPA
Hg19::chr20:33462829..33462852,+	p5@ACSS2
Hg19::chr20:33462854..33462864,+	p10@ACSS2
Hg19::chr20:33462888..33462894,+	p12@ACSS2
Hg19::chr20:44645128..44645150,+	p@chr20:44645128..44645150 +
Hg19::chr20:44645159..44645166,+	p@chr20:44645159..44645166 +
Hg19::chr20:45179283..45179298,-	p1@C20orf123
Hg19::chr2:217362648..217362677,+	p3@RPL37A
Hg19::chr2:9562702..9562734,-	p5@ITGB1BP1
Hg19::chr2:96782206..96782211,-	p3@ADRA2B
Hg19::chr2:97012141..97012156,+	p@chr2:97012141..97012156 +
Hg19::chr3:105717313..105717328,+	p@chr3:105717313..105717328 +
Hg19::chr3:129334636..129334653,-	p1@BC025331
Hg19::chr3:188665020..188665032,+	p10@TPRG1
Hg19::chr3:196046974..196046977,-	p@chr3:196046974..196046977 -
Hg19::chr3:196065248..196065267,-	p1@TM4SF19
Hg19::chr4:48807155..48807187,+	p13@OCIAD1
Hg19::chr4:682935..682946,-	p2@MFSD7
Hg19::chr5:137330846..137330858,-	p@chr5:137330846..137330858 -
Hg19::chr5:147789958..147789969,+	p5@FBXO38
Hg19::chr6:160183931..160183971,+	p@chr6:160183931..160183971 +
Hg19::chr6:164082461..164082467,-	p@chr6:164082461..164082467 -
Hg19::chr6:164082471..164082476,-	p@chr6:164082471..164082476 -
Hg19::chr6:164082477..164082487,-	p@chr6:164082477..164082487 -
Hg19::chr6:33111201..33111222,-	p1@HLA-DPA3
Hg19::chr6:4346987..4346998,-	p@chr6:4346987..4346998 -
Hg19::chr6:4347006..4347027,-	p@chr6:4347006..4347027 -
Hg19::chr6:46700055..46700067,-	p@chr6:46700055..46700067 -
Hg19::chr7:128543401..128543428,-	p2@KCP
Hg19::chr7:137308..137321,+	p@chr7:137308..137321 +
Hg19::chr7:137336..137341,+	p@chr7:137336..137341 +
Hg19::chr7:139762438..139762447,-	p4@PARP12
Hg19::chr7:150477549..150477560,-	p@chr7:150477549..150477560 -
Hg19::chr7:73507534..73507583,+	p2@LIMK1
Hg19::chr8:102216925..102216938,-	p7@ZNF706
Hg19::chr8:105670277..105670285,-	p@chr8:105670277..105670285 -
Hg19::chr8:18680942..18680953,-	p@chr8:18680942..18680953 -
Hg19::chr8:87111132..87111146,+	p1@ATP6V0D2
Hg19::chr9:115945404..115945413,-	p@chr9:115945404..115945413 -
Hg19::chr9:124030049..124030099,+	p7@GSN
Hg19::chr9:86983624..86983647,-	p2@SLC28A3
Hg19::chr9:86983657..86983666,-	p4@SLC28A3
Hg19::chr9:86983667..86983668,-	p11@SLC28A3
Hg19::chrX:149867720..149867743,+	p@chrX:149867720..149867743 +

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

p.value	FDR	nGenes	nPathway	Name
6.08120276742328e-05	0.0384940135177894	4	156	Phagosome (KEGG):04145

Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0005765	lysosomal membrane	0.00512780967323701
GO:0005774	vacuolar membrane	0.00512780967323701
GO:0044437	vacuolar part	0.00512780967323701
GO:0005764	lysosome	0.00512780967323701
GO:0000323	lytic vacuole	0.00512780967323701
GO:0005773	vacuole	0.00743018613799899
GO:0045807	positive regulation of endocytosis	0.0110236329171431
GO:0030100	regulation of endocytosis	0.0329666922785616
GO:0048518	positive regulation of biological process	0.0329666922785616
GO:0051050	positive regulation of transport	0.0329666922785616
GO:0004715	non-membrane spanning protein tyrosine kinase activity	0.0329666922785616
GO:0005737	cytoplasm	0.0329666922785616
GO:0005768	endosome	0.0329666922785616
GO:0050265	RNA uridylyltransferase activity	0.0329666922785616
GO:0010324	membrane invagination	0.0329666922785616
GO:0006897	endocytosis	0.0329666922785616
GO:0005770	late endosome	0.037051496732088
GO:0001798	positive regulation of type IIa hypersensitivity	0.0419341731288713
GO:0002894	positive regulation of type II hypersensitivity	0.0419341731288713
GO:0001796	regulation of type IIa hypersensitivity	0.0419341731288713
GO:0002886	regulation of myeloid leukocyte mediated immunity	0.0419341731288713
GO:0002445	type II hypersensitivity	0.0419341731288713
GO:0001794	type IIa hypersensitivity	0.0419341731288713
GO:0002888	positive regulation of myeloid leukocyte mediated immunity	0.0419341731288713
GO:0002892	regulation of type II hypersensitivity	0.0419341731288713
GO:0048522	positive regulation of cellular process	0.0424802110626503
GO:0016044	membrane organization and biogenesis	0.0424802110626503
GO:0005534	galactose binding	0.0424802110626503
GO:0002712	regulation of B cell mediated immunity	0.0424802110626503
GO:0002863	positive regulation of inflammatory response to antigenic stimulus	0.0424802110626503
GO:0002885	positive regulation of hypersensitivity	0.0424802110626503
GO:0002866	positive regulation of acute inflammatory response to antigenic stimulus	0.0424802110626503
GO:0002675	positive regulation of acute inflammatory response	0.0424802110626503
GO:0002889	regulation of immunoglobulin mediated immune response	0.0424802110626503
GO:0002891	positive regulation of immunoglobulin mediated immune response	0.0424802110626503
GO:0002714	positive regulation of B cell mediated immunity	0.0424802110626503
GO:0045737	positive regulation of cyclin-dependent protein kinase activity	0.0424802110626503
GO:0051179	localization	0.0427484246496105
GO:0044440	endosomal part	0.0427484246496105
GO:0010008	endosome membrane	0.0427484246496105
GO:0004713	protein-tyrosine kinase activity	0.0427484246496105
GO:0048247	lymphocyte chemotaxis	0.0427484246496105
GO:0051014	actin filament severing	0.0427484246496105
GO:0002861	regulation of inflammatory response to antigenic stimulus	0.0427484246496105
GO:0002673	regulation of acute inflammatory response	0.0427484246496105
GO:0004938	alpha2-adrenergic receptor activity	0.0427484246496105
GO:0002864	regulation of acute inflammatory response to antigenic stimulus	0.0427484246496105
GO:0002883	regulation of hypersensitivity	0.0427484246496105
GO:0004334	fumarylacetoacetase activity	0.0427484246496105
GO:0051258	protein polymerization	0.0446980703271029
GO:0005415	nucleoside:sodium symporter activity	0.0484642556070935
GO:0006572	tyrosine catabolic process	0.0484642556070935
GO:0008061	chitin binding	0.0484642556070935
GO:0001882	nucleoside binding	0.0484642556070935
GO:0051049	regulation of transport	0.049824750361269
GO:0044464	cell part	0.049824750361269
GO:0045773	positive regulation of axon extension	0.049824750361269
GO:0002437	inflammatory response to antigenic stimulus	0.049824750361269
GO:0016823	hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances	0.049824750361269
GO:0002524	hypersensitivity	0.049824750361269
GO:0016822	hydrolase activity, acting on acid carbon-carbon bonds	0.049824750361269
GO:0015198	oligopeptide transporter activity	0.049824750361269
GO:0002438	acute inflammatory response to antigenic stimulus	0.049824750361269

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>

---

Cell Type

Ontology term	p-value	n
myeloid leukocyte	8.22e-32	76
granulocyte monocyte progenitor cell	2.49e-31	71
macrophage dendritic cell progenitor	4.76e-29	65
monopoietic cell	8.75e-28	63
monocyte	8.75e-28	63
monoblast	8.75e-28	63
promonocyte	8.75e-28	63
myeloid lineage restricted progenitor cell	8.93e-28	70
myeloid cell	3.02e-24	112
common myeloid progenitor	3.02e-24	112
CD14-positive, CD16-negative classical monocyte	6.08e-24	42
classical monocyte	2.31e-20	45
leukocyte	4.33e-11	140
hematopoietic oligopotent progenitor cell	3.02e-09	165
hematopoietic multipotent progenitor cell	3.02e-09	165
hematopoietic lineage restricted progenitor cell	6.58e-09	124
hematopoietic stem cell	2.87e-08	172
angioblastic mesenchymal cell	2.87e-08	172
mesenchymal cell	4.87e-08	358
hematopoietic cell	8.03e-08	182
nongranular leukocyte	1.10e-07	119
connective tissue cell	4.44e-07	365
multi fate stem cell	5.30e-07	430

Uber Anatomy

Ontology term	p-value	n
immune system	3.60e-28	115
bone marrow	2.78e-27	80
hemolymphoid system	2.45e-26	112
hematopoietic system	9.08e-26	102
blood island	9.08e-26	102
bone element	1.27e-23	86
skeletal element	5.20e-20	101
skeletal system	5.20e-20	101
lateral plate mesoderm	2.56e-13	216
musculoskeletal system	2.26e-12	167
adult organism	8.00e-10	115
anatomical system	2.01e-08	625
anatomical group	2.32e-08	626
tissue	1.73e-07	787
organ	3.43e-07	511

Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}

ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data

---

No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data

---

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.